Whitehead Institute for Biomedical Research

Other

Massachusetts Institute of Technology

Harvard College

The United States of America as Represented by the Department of Health

The Rockefeller University

Whitehead Insti.

David Baltimore

Phillip A Sharp

Michael J Lenardo

Albert S Baldwin

Thomas P Maniatis

Louis Staudt

Didier Trono

Chen-Ming Fan

Patrick A Baeuerle

Lynn M Corcoran

Ranjan Sen

Harinder Singh

Jonathan H Lebowitz

Roger G Clerc

Richard A Young

Anna Aldovini

Mark B Feinberg

Robert H Purcell

Seth Lederman

Stephen M Feinstone

John R Ticehurst

Genhong Cheng

Aileen Anne Cleary

Zheng-Sheng Ye

Bahige M Baroudy

Kalle M Saksela

A system and method for analyzing a biological substance, the device comprising: a specimen input device; at least one pumping device in flow communication with a chemical reservoir and said specimen input device; and at least one flow cell in flow communication with said at least one pumping device via at least one flow valve, wherein said at least one flow cell is configured to contain said specimen and includes a sensing device configured to sense at least one characteristic of said specimen.

System and method for analyzing a biological sample

Overexpression of a CRAF1 (CD40 receptor-associated factor 1) gene truncated by 323 to about 414 amino acids at the amino inhibits CD40-mediated cell activation, and is used to treat conditions characterized by an unwanted level of CD40-mediated intracellular signaling.

Truncated CRAF1 inhibits CD40 signaling

Constitutive and tissue-specific protein factors which bind to transcriptional regulatory elements of Ig genes (promoter and enhancer) are described. The factors were identified and isolated by an improved assay for protein-DNA binding. Genes encoding factors which positively regulate transcription can be isolated and employed to enhance transription of Ig genes. In particular, NF-kB, the gene encoding NF-kB, IkB and the gene encoding IkB and uses therefor.

Nuclear factors associated with transcriptional regulation

This invention related to constructs comprising mutant HIV genomes having an alteration in a nucleotide sequence which is critical for genomic RNA packaging and non-infectious, immunogenic HIV particles produced by expression of these constructs in mammalian cells. Cell lines which stably produce non-infectious, immunogenic HIV particles are also included. Prophylactic and therapeutic vaccines, diagnostic reagents, and related methods are further described.

Non-infectious HIV particles and uses therefor

Nuclear factors associates with transcriptional regulation

This invention relates to the prognosis of outcome of infection with the human immunodeficiency virus (HIV). In particular, the present invention concerns monitoring individuals who are at risk for developing acquired immunodeficiency syndrome (AIDS), and individuals who are undergoing therapy for AIDS. The method for estimating the risk of the onset of a clinical event associated with infection with HIV broadly comprises evaluating the rate of HIV replication in peripheral blood cells from an individual suspected of suffering from HIV infection. More particularly, the method comprises determining the level of expression of HIV messenger RNA (mRNA) in peripheral blood cells of an asymptomatic individual. High level expression of HIV mRNA indicates a high likelihood of onset of symptoms of AIDS, and low level expression or determination of no detectable expression indicates a low likelihood of onset of symptoms of AIDS. In a specific embodiment, the level of HIV-1 mRNA, specifically multiply spliced (MS) and unspliced (US) HIV mRNA, is detected in peripheral blood cells from HIV-infected individuals, and the detection of high levels of HIV mRNA is predictive of the onset of clinical symptoms associated with disease progression, including the diagnosis of AIDS, a decrease in the number of CD4+ cells to below 500 CD4+ cells per mm.sup.3, and other clinical events. According to the invention, the onset of clinical AIDS generally occurs within about 2 years of the determination of high level expression of HIV mRNA, and the onset of clinical symptoms generally does not occur for at least about 5 years after the determination of no detectable expression of HIV mRNA.

Methods for the prognosis and monitoring of AIDS

Methods for producing HAV cDNA, products thereof, and uses thereof, are described. HAV cDNA is produced, for example, by reverse transcribing HAV RNA and subsequently inserting the HAV cDNA into bacterial plasmids by genetic-engineering techniques. Transformed bacteria are then cloned and cultured to produce replicated chimetic plasmids containing the HAV cDNA. Such HAV cDNA is useful in assaying for the presence of HAV and in the production of HAV antigen and in the production of antibodies against HAV.

Methods of detecting hepatitis A virus

A construct which includes a cap independent 5' noncoding region of viral or cellular origin and a nucleotide sequence of interest, which is located downstream of the noncoding region. A method of producing a protein or a polypeptide of interest by introducing the construct, including a nucleotide sequence encoding the protein or the polypeptide of interest, into mammalian cells is also described. In one embodiment, the construct comprises all or a portion of the poliovirus cap independent 5' noncoding region and a nucleotide sequence encoding a protein or a polypeptide of interest.

Gene expression in mammalian cells using a cap independent 5' noncoding

Growing community of inventors

New York, NY, United States of America

David Baltimore